10x Genomics, Inc. (TXG) Financial Statements

Executive TeamFinancials
SegmentsShareholders

10x Genomics financial statements at a glance

10x Genomics reported revenue of $642.82 million for fiscal year 2025 (ended December 31, 2025), up 5.2% from fiscal year 2024. Net income was -$43.54 million, a net margin of 6.8% loss, and diluted earnings per share were -$0.35.

At the end of fiscal year 2025 it had total assets of $1.04 billion, total liabilities of $245.04 million and shareholders' equity of $796.33 million, with cash and short-term investments of $523.41 million and total debt of $84.36 million.

Its operations brought in $136.05 million of cash; capital spending was $5.94 million, leaving free cash flow of $130.12 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

TXG logo

10x Genomics, Inc.

TXGUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
642.82M
Prev Year: 610.78M
YoY: +5.2%
Operating Revenue
642.82M
Prev Year: 610.78M
YoY: +5.2%
Normalized EBITDA
-45.99M
Prev Year: -133.99M
YoY: +65.7%
Tax Rate for Calcs
0.21
Prev Year: 0
Tax Effect of Unusual Items
10.48M
Total Unusual Items
49.90M
Total Unusual Items Excluding Goodwill
49.90M
Interest Income
20.05M
Prev Year: 18.45M
YoY: +8.7%
Special Income Charges
49.90M
Other Special Charges
-49.90M
Non-operating Interest Income
20.05M
Prev Year: 18.45M
YoY: +8.7%
Cost of Revenue
198.94M
Prev Year: 196.30M
YoY: +1.3%
Gross Profit
443.88M
Prev Year: 414.48M
YoY: +7.1%
Operating Expense
554.77M
Prev Year: 609.04M
YoY: -8.9%
Selling General and Administrative
316.13M
Prev Year: 344.34M
YoY: -8.2%
Research and Development
238.63M
Prev Year: 264.70M
YoY: -9.8%
Operating Income
-110.89M
Prev Year: -194.56M
YoY: +43.0%
Net Non Operating Interest Income Expense
20.05M
Prev Year: 18.44M
YoY: +8.7%
Other Income Expense
50.93M
Prev Year: -1.58M
YoY: +3313.2%
Other Non-operating Income (expense)
1.03M
Prev Year: -1.58M
YoY: +165.0%
Pre-tax Income
-39.91M
Prev Year: -177.70M
YoY: +77.5%
Provision for Income Taxes
3.64M
Prev Year: 4.93M
YoY: -26.2%
Net Income Common Stockholders
-43.54M
Prev Year: -182.63M
YoY: +76.2%
Net Income
-43.54M
Prev Year: -182.63M
YoY: +76.2%
Net Income Including Non-Controlling Interests
-43.54M
Prev Year: -182.63M
YoY: +76.2%
Net Income from Continuing Operations
-43.54M
Prev Year: -182.63M
YoY: +76.2%
Diluted NI Available to Com Stockholders
-43.54M
Prev Year: -182.63M
YoY: +76.2%
Basic EPS
-0.35
Prev Year: -1.52
YoY: +77.0%
Diluted EPS
-0.35
Prev Year: -1.52
YoY: +77.0%
Weighted Average Shares (basic)
124.75M
Prev Year: 120.45M
YoY: +3.6%
Weighted Average Shares (diluted)
124.75M
Prev Year: 120.45M
YoY: +3.6%
Total Operating Income as Reported
-60.98M
Prev Year: -194.56M
YoY: +68.7%
Total Expenses
753.71M
Prev Year: 805.34M
YoY: -6.4%
Net Income from Continuing and Discontinued Operation
-43.54M
Prev Year: -182.63M
YoY: +76.2%
Normalized Income
-82.97M
Prev Year: -182.63M
YoY: +54.6%
Net Interest Income
20.05M
Prev Year: 18.44M
YoY: +8.7%
EBIT
-39.91M
Prev Year: -177.70M
YoY: +77.5%
EBITDA
3.91M
Prev Year: -133.99M
YoY: +102.9%
Reconciled Cost of Revenue
198.94M
Prev Year: 196.30M
YoY: +1.3%
Reconciled Depreciation
43.82M
Prev Year: 43.71M
YoY: +0.2%
Net Income from Continuing Operation Net Minority Interest
-43.54M
Prev Year: -182.63M
YoY: +76.2%
Values in USD

10x Genomics key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$642.8M$610.8M$618.7M$516.4M$490.5M
Gross profit$443.9M$414.5M$409.3M$396.0M$416.4M
Operating income-$110.9M-$194.6M-$204.3M-$167.9M-$52.9M
Net income-$43.5M-$182.6M-$255.1M-$166.0M-$58.2M
Diluted EPS-$0.35-$1.52-$2.18-$1.46-$0.53
Total assets$1.0B$918.6M$965.1M$1.0B$1.0B
Total liabilities$245.0M$208.5M$224.1M$223.2M$201.3M
Shareholders' equity$796.3M$710.1M$741.0M$805.7M$817.6M
Cash and short-term investments$523.4M$393.4M$388.7M$430.0M$587.4M
Total debt$84.4M$82.6M$95.4M$95.2M$82.0M
Operating cash flow$136.1M$6.7M-$15.2M-$33.6M-$21.4M
Capital spending$5.9M$13.4M$49.5M$131.7M$101.3M
Free cash flow$130.1M-$6.7M-$64.7M-$165.3M-$122.7M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2017.

Questions and answers

What was 10x Genomics's revenue in fiscal year 2025?

$642.82 million, up 5.2% from $610.79 million in fiscal year 2024.

How much profit does 10x Genomics make?

10x Genomics reported net income of -$43.54 million for fiscal year 2025 (6.8% of revenue); operating income was -$110.89 million.

How much cash and debt does 10x Genomics have?

At the end of fiscal year 2025: cash and short-term investments of $523.41 million and total debt of $84.36 million.

What is 10x Genomics's free cash flow?

$130.12 million in fiscal year 2025 (operating cash flow of $136.05 million minus capital spending of $5.94 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube